BEUDAMED
    4,549 results · 48ms · Sources: EU EUDAMED, US FDA

    active MED

    Device
    EU MDR · Eu Md Class 1 ·PS Product Services GmbH·On the market

    active MED

    Device
    EU MDR · Eu Md Class 1 ·PS Product Services GmbH·On the market

    active MED

    Device
    EU MDR · Eu Md Class 1 ·PS Product Services GmbH·On the market

    Curafit

    Device
    EU MDR · Eu Md Class 1 ·PS Product Services GmbH·On the market

    Curafit

    Device
    EU MDR · Eu Md Class 1 ·PS Product Services GmbH·On the market

    Curafit

    Device
    EU MDR · Eu Md Class 1 ·PS Product Services GmbH·On the market

    elkos

    Device
    EU MDR · Eu Md Class 1 ·PS Product Services GmbH·On the market

    Vitalis

    Device
    EU MDR · Eu Md Class 1 ·PS Product Services GmbH·On the market

    Vitalis

    Device
    EU MDR · Eu Md Class 1 ·PS Product Services GmbH·On the market

    active MED

    Device
    EU MDR · Eu Md Class 1 ·PS Product Services GmbH·On the market

    activeMed

    Device
    EU MDR · Eu Md Class 1 ·PS Product Services GmbH·On the market

    FDA Pre-Market Approval
    IMMULITE® PSA, IMMULITE® 2000 PSA, IMMULITE® Third Generation PSA, IMMULITE® 2000 Third Generation PSA

    Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer

    FDA Pre-Market Approval
    FDA Class 3 ·ARCHITECT Total PSA / Alinity i Total PSA

    Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions

    FDA Pre-Market Approval
    FDA Class 3 ·ARCHITECT Free PSA / Alinity i Free PSA

    Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer

    FDA Pre-Market Approval
    FDA Class 3 ·ARCHITECT Total PSA / Alinity i Total PSA

    Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer

    FDA Pre-Market Approval
    FDA Class 3 ·ARCHITECT TOTAL PSA AND AXSYM TOTAL PSA

    Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions

    FDA Pre-Market Approval
    FDA Class 3 ·ARCHITECT Free PSA / Alinity i Free PSA

    Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer

    FDA Pre-Market Approval
    FDA Class 3 ·ARCHITECT Total PSA, Alinity i Total PSA

    Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions

    FDA Pre-Market Approval
    FDA Class 3 ·AXSYM FREE PSA & ARCHITECT FREE PSA

    Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer

    FDA Pre-Market Approval
    FDA Class 3 ·Immulite/Immulite 1000 PSA/Immulite 2000 PSA